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Abstract
Background: Meningiomas of the skull base account for 25–30% of all meningiomas. Due to the complex structure
of the cranial base and its close proximity to critical structures, surgery is often associated with substantial
morbidity. Treatment options include observation, aggressive surgical intervention, stereotactic or conventional
radiotherapy.
In this analysis we evaluate the outcome of 110 patients with meningiomas of the skull base treated with particle
therapy. It was performed within the framework of the “clinical research group heavy ion therapy” and supported
by the German Research Council (DFG, KFO 214).
Methods: Between May 2010 and November 2014, 110 Patients with skull base meningioma were treated with
particle radiotherapy at the Heidelberg Ion Therapy Center (HIT). Primary localizations included the sphenoid wing
(n = 42), petroclival region (n = 23), cavernous sinus (n = 4), sella (n = 10) and olfactory nerve (n = 4). Sixty
meningiomas were benign (WHO °I); whereas 8 were high-risk (WHO °II (n = 7) and °III (n = 1)). In 42 cases histology
was not examined, since no surgery was performed.
Proton (n = 104) or carbon ion (n = 6) radiotherapy was applied at Heidelberg Ion Therapy Center (HIT) using raster-
scanning technique for active beam delivery. Fifty one patients (46.4%) received radiotherapy due to tumor
progression, 17 (15.5%) after surgical resection and 42 (38.2%) as primary treatment.
Results: Median follow-up in this analysis was 46,8 months (95% CI 39,9–53,7; Q1-Q3 34,3–61,7). Particle
radiotherapy could be performed safely without toxicity-related interruptions. No grade IV or V toxicities according
to CTCAE v4.0 were observed. Particle RT offered excellent overall local control rates with 100% progression-free
survival (PFS) after 36 months and 96.6% after 60 months. Median PFS was not reached due to the small number of
events. Histology significantly impacted PFS with superior PFS after 5 years for low-risk tumors (96.6% vs. 75.0%,
p = 0,02). Overall survival was 96.2% after 60 months and 92.0% after 72 months from therapy. Of six documented
deaths, five were definitely not and the sixth probably not meningioma-related.
(Continued on next page)
* Correspondence: rami.elshafie@med.uni-heidelberg.de
†Equal contributors
1Department of Radiation Oncology, University Hospital of Heidelberg, Im
Neuenheimer Feld 400, 69120 Heidelberg, Germany
7Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld
400, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
El Shafie et al. Radiation Oncology  (2018) 13:54 
https://doi.org/10.1186/s13014-018-1002-5
(Continued from previous page)
Conclusion: Particle radiotherapy is an excellent treatment option for patients with meningiomas of the skull base
and can lead to long-term tumor control with minimal side effects. Other prospective studies with longer follow-up
will be necessary to further confirm the role of particle radiotherapy in skull base meningioma.
Keywords: Proton therapy, Carbon ion therapy, Active raster-scanning, Skull base, Toxicity, Quality of life,
Radiotherapy, Radiotolerance, Benign, Malignant
Background
Meningiomas account for approximately one third of all
primary brain tumors and tumors of the central nervous
system [1]. Most are benign, slow growing lesions origin-
ating from the arachnoidal cap cells, with the skull base
being the most frequent localization [2]. Besides benign
histology, a smaller number of meningiomas can be of
atypical or anaplastic histology, characterized by aggres-
sive growth patterns and a high rate of recurrence [3].
Many analyses focus on meningiomas of the skull base
because of its intricate anatomy and the close proximity
to vascular structures, cranial nerves and the brainstem;
consequently treatment in those cases is challenging and
treatment options are controversially discussed.
Surgical resection has for long been the treatment of
choice but in the last decades advances in radiotherapy
(RT) such as radiosurgery, fractionated stereotactic
radiotherapy (FSRT), or intensity-modulated radiother-
apy (IMRT) have made radiotherapy an important treat-
ment alternative [4, 5]. Due to the complex anatomy of
the skull base, tumor adherence to bony structures and
the close proximity to sensitive organs at risk (OAR),
total resection is often not possible as it may cause to
substantial morbidity. Consequently, as neurosurgical re-
section is subtotal in many cases, it cannot achieve high
long-term local control and overall survival rates [6].
Additional radiotherapy can improve chances for long-
term tumor control [7].
Meningiomas are often discovered incidentally or present
with only mild symptoms and indolent growth patterns. In
those cases, there is no urgent need for therapeutic inter-
vention. Active surveillance can be a reasonable approach,
focusing on precise high-resolution contrast-enhanced
magnetic resonance imaging (MRI) and clinical examina-
tions in regular intervals (e.g. every six to 12 months, pro-
vided an asymptomatic/stable clinical situation). However,
if the tumor enlarges significantly during the course of neu-
roimaging or clinical symptoms develop or worsen, treat-
ment becomes mandatory [6].
Particle beams, such as protons and heavier ion beams
like carbon ions offer high precision when it comes to
dose application to the tumor volume so that OAR can
be very effectively spared [8, 9].
With its unique physical characteristics, including the
inverted dose profile, high local dose deposition within
the Bragg Peak and a steep falloff outside the treatment
volume, particle radiation therapy leads to a greater dose
conformity than photon RT [10]. Compared to protons,
carbon ions additionally offer the advantage of higher
biological efficiency with a relative biological effective-
ness (RBE) ranging between 3 and 5, potentially leading
to higher local control rates [11].
To date, particle therapy at Heidelberg Ion Therapy
Center (HIT) has been integrated into the clinical envir-
onment at our institution for close to a decade and is
constantly being validated for the treatment of skull base
meningiomas. In this present study, we analyse our re-
sults for skull base meningiomas in 110 patients treated
with particle therapy – protons as well as carbon ions –
with special focus on treatment outcome and toxicity.
Methods
Patient characteristics and histology
In the present analysis we included 110 consecutive pa-
tients with meningiomas of the skull base that had not
previously received radiotherapy. All patients received
particle therapy – either with proton beams or carbon
ion beams – at the Heidelberg Ion Therapy Center
(HIT). One hundred four patients received proton
therapy, 6 patients received carbon ion radiotherapy. All
patients were enrolled in a close follow-up program, con-
sisting of neuroimaging as well as clinical-neurological as-
sessments. According to WHO classification, 60 (54.5%)
meningiomas were categorized as benign (WHO grade I).
In 8 patients (7.3%) a high-risk histology was observed, in-
cluding 7 (6.4%) WHO grade II and 1 (0.9%) WHO grade
III. In a total of 42 patients (38.2%) histology was un-
known, since surgery was not performed. The diagnosis in
these cases was based on clinical presentation in combin-
ation with imaging, consisting of MRI as well as computed
tomography (CT), revealing the typical attributes of
meningiomas. In some cases an additional FET or Ga68–
DOTATOC-PET examination was performed to support
the diagnosis.
Tumor location
The exact locations of the meningiomas were ascer-
tained by reviewing all images used for treatment
planning. Often, tumors had ambiguous extent into
structures of the skull base and extended into several
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regions. In those cases we focused on main tumor ex-
tension and tumor origin to create a common classifi-
cation.Patient characteristics, histology and tumor
locations are listed in Table 1.
Previous surgery
In most patients, previous neurosurgical intervention
had been performed: 69 patients (62.7%) had at least one
surgical intervention, which was either subtotal or a bi-
opsy in 66 patients and complete in only 3 patients.
Nine patients had an unknown course of surgery. In 29
patients (26.4%) undergoing surgery, more than one
intervention had been performed in the past and 8 pa-
tients (7.3%) received three or more interventions. In a
total of 51 cases (46.4%) RT was performed due to
tumor progression, 42 patients (38.2%) received radi-
ation therapy as a definite treatment with some patients
undergoing a biopsy beforehand. In 17 patients (15.5%)
RT was performed after surgical resection.
Pre-treatment imaging
For immobilization purposes, an individual custom-made
thermoplastic mask was used throughout the entire treat-
ment program. Treatment planning was based on a high-
resolution CT scan (native and contrast-enhanced, 3 mm
slice thickness). For target volume definition the treatment
planning CT imaging data was in all cases matched to a
contrast-enhanced MRI with a maximum slice thickness
of 3 mm, including a T1-weighted contrast-enhanced
sequence to allow for a more precise estimate of tumor
extension. In 52 cases (47.3%) an additional FET- and/or
DOTATOC-PET was performed to further facilitate target
volume definition. Particle irradiation was delivered using
active rasterscanning for both protons and carbon ions,
applying one fraction a day, 6 days a week.
Treatment planning for proton therapy
Low-risk meningiomas (WHO grade I or unknown, n =
102) were treated with proton therapy. Two patients with
higher grade meningeomas (grade II n = 1, grade III n = 1)
were also treated with proton therapy. Those patients had
previously received radiotherapy for other cranial tumors
(retinoblastoma in one case and a different meningioma
in a non-overlapping area in the other) and the moder-
ately hypofractionated approach of carbon ion radiother-
apy (3 Gy(RBE) per fraction) combined with the higher
biological effectiveness was deemed not ideal in those
cases with previous dose to OAR. Proton therapy was thus
preferred in those two cases. Target volume delineation
for proton therapy was performed as follows: On the T1-
weighted sequence contrasted tumor formations were de-
lineated as gross tumor volume (GTV). To define the clin-
ical target volume (CTV) a safety margin of 1–2 mm
(benign histology) or 5 mm (malignant histology) was
added and adapted at the discretion of the treating phys-
ician including adjoining meningeal enhancement (dural
tail) and areas of potential microscopic spread. An iso-
tropic PTV margin of 3 mm was added in all cases to
compensate for positioning and technical insecurities, as
Table 1 Patient characteristics





Mean (SD) 53 11.7
Median (Q1-Q3) 52 29–85
Median (range) 52 45–59
Histology
WHO I 60 54.5%
WHO II 7 6.4%
WHO III 1 0.9%
unknown 42 38.2%
Location
sphenoid wing 42 38.2%
petroclival 23 20.9%
sphenoorbital 13 11.8%
supra- and/or parasellar region 10 9.1%
sinus cavernosus 4 3.6%
olfactory 4 3.6%
tentorial fold 3 2.7%
petrosal 5 4.5%
cerebello-pontine angle 3 2.7%
foramen magnum 3 2.7%
Karnofsky performance score
≥ 80% 101 91.8%
< 80% 9 8.2%
Previous surgery
partial resection 62 56.4%
no surgery 32 29.1%
unknown 9 8.2%
biopsy 4 3.6%
complete resection 3 2.7%
treatment setting
due to tumor progression 51 46.4%
definite 42 38.2%
adjuvant / additive 17 15.5%
Particle therapy
protons 104 94.5%
carbon ions 6 5.5%
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is standard procedure for intracranial irradiation at HIT.
Details of resulting target volume sizes are illustrated in
Table 2. Generally, coverage by the prescribed dose was
optimized for CTV; focally reduced PTV coverage was
tolerated to allow for OAR sparing in cases of necessity.
Median cumulative dose for proton irradiation was
54 Gy(RBE) (range 50–60 Gy(RBE)) at a dose per fraction
of 1,8 (n = 57) or 2 (n = 47) Gy(RBE).
Treatment planning for carbon ion therapy
High-risk meningeomas (WHO grades II and III, n = 6)
were treated with a carbon ion boost after having received
a median cumulative dose of 50 Gy (range 48,4–55,8 Gy) of
photon irradiation. Target volume delineation and dose pre-
scription were performed analogous to the MARCIE trial, a
prospective trial being conducted at our institution for the
treatment of atypical meningeomas [3]. For carbon ion ir-
radiation contrast-enhanced areas on the T1-weighted MRI
sequence were delineated as GTV with a 5 mm CTV mar-
gin that could be adapted at the discretion of the treating
physician (e.g. to respect anatomic boundaries). An iso-
tropic PTV margin of 3 mm was added as explained earlier.
Details of resulting target volume sizes are illustrated in
Table 2. Carbon ion dose prescribed in all cases was
18 Gy(RBE) at a dose per fraction of 3 Gy(RBE).
Follow-up procedure
Patients were followed up prospectively after completion
of particle therapy as described previously [12]. Clinical
examinations, including ophthalmological and neuro-
logical evaluations if needed and contrast-enhanced MR
imaging were scheduled initially 6 weeks after RT.
Thereafter, patients were followed up every 3 months in
the first year and then every 6–12 months in the follow-
ing years when no clinical or imaging-based signs of
tumor progression occurred. Procedure for every follow-
up visit would consist of a contrast-enhanced MRI as
well as thorough clinical check-up. To complete or up-
date follow-up information, we contacted patients lost to
follow-up directly by phone or correspondence asking
for clinical neurological assessments as well as current
medical imaging. Four patients could not be contacted
and were lost to follow-up.
Symptoms and toxicities were documented in detail in
the patient’s medical record and subsequently entered into
a prospective research database maintained at our institu-
tion for long-term systematic follow-up of radiooncologi-
cal patients [12]. Symptoms were classified according to
the Common Terminology Criteria for Adverse Events
(CTCAE) v4.0 [13]. New or worsening symptoms were
considered acute and treatment-related toxicities if they
occurred within the first 6 months after radiotherapy and
late toxicities if they occurred after that. Symptoms were
followed up and outcome was judged clinically as either
stable/improved or worsened. Toxicities of grades I and II
according to CTCAE were classified low-grade. Any de
novo symptoms grade III or higher were classified high-
grade, as were any pre-existing symptoms worsening by at
least two CTCAE grades except if directly attributable to
tumor progression.
Statistics
For descriptive baseline analyses, continous variables are
given as means (SD) and median (quartiles, range where
appropriate) and categorical variables as absolute and
relative frequencies. The median follow-up time was cal-
culated using the reverse Kaplan-Meier method [14].
Overall survival (OS) and progression-free survival (PFS)
were both determined using the actuarial method of
Kaplan-Meier. OS was calculated from the date of the
first diagnosis to last follow-up or death and separately
from the beginning of radiotherapy to last follow-up or
death. PFS was determined from the day of first RT to
the date of occurrence of one of the following: last
follow-up/tumor progression/death. Survival curves for
prognostic factors were compared using a two-sided log-
rank test. Since this was a retrospective exploratory data
analysis p-values are of descriptive nature. A descriptive
p-value of < 0.05 was considered to indicate statistical
significance. Toxicity was classified according to CTCAE
v4.0 and assessed descriptively, giving absolute and rela-
tive frequencies for each symptom. Improvement or
worsening of a certain symptom was judged clinically on
a case-by-case basis. Statistical analyses were performed
with the software IBM SPSS Statistics Version 22 (New
York, USA).
Results
Local tumor control and survival
The reverse Kaplan-Meier estimate for median follow-
up was 46,8 months (95% CI 39,9–53,7; Q1-Q3 34,3–
61,7) for progression-free survival and 57,97 month
(95% CI 50,6–62,5; Q1-Q3 38,3–68,9) for overall sur-
vival. Progression-free survival rate for all patients
treated with particle therapy was 100% after 36 months
Table 2 Target volume sizes
median (ml) Q1-Q3 (ml) mean (ml) std dev (ml)
Target volumes for proton irradiation
GTV 22,6 12,5–35,1 28,7 25,9
CTV 31,5 19,2–49,9 44,5 42,4
PTV 50,8 32,7–76,3 68,0 57,5
Target volumes for carbon ion boost irradiation
GTV 54,6 38,4–59,8 47,3 22,3
CTV 46,9 42–77,8 58,5 29,3
PTV 65,7 59,6–112 82,1 38,8
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and 96.6% after 60 months. In total, four patients
showed local progression. Median PFS was not reached
due to the small number of events. Median time to pro-
gression was 55,6 months (Q1-Q3 45,2–65,1; range
40,0–67,3 months) (Fig. 1). Histology significantly im-
pacted PFS with inferior PFS at 60 months (75.0% for
high-risk vs. 96.6% for low-risk histology, p = 0,02) (Fig. 2)
, although notably there were only eight patients and one
event in the high-risk group, adding to the fact that hist-
ology at primary diagnosis was unknown for 38.2% of the
patients and thus limiting the conclusions to be drawn on
this data regarding the impact of histology.
Overall survival from the beginning of particle ther-
apy was 96.2% after 60 months and 92.0% after
72 months. Median OS was not reached due the
small number of events (Fig. 3). OS from the date of
initial diagnosis was 98.1% after 10 years and 90.7%
after 15 years (Fig. 4). In total, there were six deaths,
for five of which the cause could reliably be deter-
mined. None of those deaths was meningioma-related.
Two patients died of other oncologic illnesses (pan-
creatic (n = 1) and ovarian cancer (n = 1)). Two pa-
tients died of substantial cardiovascular co-morbidities
and one patient died of a pre-existing advanced-stage
normal pressure hydrocephalus. The latter three pa-
tients had already been severely reduced in general
performance prior to therapy. Four deaths occurred
within the first 3 years of radiotherapy. Five deaths
occurred in the low-risk group and one in the high-
risk group. None of the patients who died had pro-
gressed at the last recorded follow-up.
Progressing patients
The four patients progressing after particle RT were
characterized as follows: The first patient was treated for
a meningioma of the intrasellar region in a definite set-
ting with 32 × 1,8 Gy(RBE) of proton irradiation without
prior surgery or biopsy. She progressed locally 39 months
thereafter and underwent partial resection, showing a
grade II meningioma, and afterwards received additive
Fig. 1 Progression-free survival for patients with skull base
meningiomas treated with paticle therapy, regardless of histology
Fig. 2 Progression-free survival for patients with skull base
meningiomas separated by low risk (WHO grade I) and high-risk
(WHO grades II and III) histology
Fig. 3 Overall survival calculated from beginning of particle therapy
for patients with skull base meningiomas treated with particle
therapy, regardless of histology
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re-irradiation with 15 × 3 Gy(RBE) carbon ion therapy.
The second patient received 25 × 2 Gy photon IMRT
and a carbon ion boost of 18 Gy(RBE) (cumulative dose
68 Gy(RBE)) after multiple partial resections of a petro-
sal WHO grade II meningioma. Local progression oc-
curred after 47 months and was treated with 15 ×
3 Gy(RBE) carbon ions as re-irradiation. He showed no
further tumor progression until last follow-up 17 months
thereafter. The third patient was treated with 28 ×
2 Gy(RBE) of proton irradiation for a meningioma of un-
known histology located in the left sphenoid wing and
parasellar region. Local progression occurred after
63 months and the patient was referred to neurosurgical
resection. The fourth patient received 27 × 2 Gy(RBE) of
proton irradiation for a partially resected WHO grade I
meningioma of the sphenoorbital region. Local progres-
sion occurred after 66 months and the patient was re-
ferred to neurosurgical resection.
Treatment-related toxicity
Treatment was overall well tolerated. All patients com-
pleted treatment successfully and no interruptions for
toxicity-associated reasons were necessary. No treatment-
related grade IV or V toxicities according to CTCAE v4.0
were observed. Acute treatment-related toxicity was mild
and mostly resolved within the first 6 months after therapy
completion. Among the most common symptoms were
focal alopecia (63.6%, n = 70), moderate fatigue (47.3%, n =
52), focal skin irritation (40.0%, n = 44) and headaches (22.
7%, n = 25). There were two cases of acute grade III
toxicity: One case of severe ulcerating mucositis requiring
hospitalization and one case of prolonged nausea due to
intracranial pressure requiring the administration of corti-
costeroids. Both cases were controllable by supportive
medication. The most common symptoms among late tox-
icity were fatigue and headaches (both 9.1%, n = 10). No
more than 10 patients reported any one symptom as late
toxicity. Overall, four cases of late CTCAE grade III toxicity
were reported: One patient with a parasellar/intrasellar
meningeoma developed massively progressive fatigue for
which the reason proved to be radiogenic hypopituitarism.
Symptoms were controlled after endocrinologic follow-up
and adequate medication. Three patients developed radio-
necrosis, two of them symptomatic (headaches, dizziness).
Delivered doses were 30 × 1,8 Gy(RBE) protons (n = 1,
interval = 9 months), 27 × 2 Gy(RBE) protons (n = 1, inter-
val = 36 months) and 5 × 3 Gy(RBE) carbon ion boost after
50 Gy photon IMRT (n = 1, interval = 7 months). To treat
radionecrosis, two patients received high-dose corticoste-
roids and one patient received Bevacizumab under which
clinical and radiologic response could be observed. An
overview of acute and late treatment-related toxicity includ-
ing respective CTCAE gradings is presented in Table 3.
Symptom response to treatment
The majority of patients presented with multiple symp-
toms pre-existing radiation therapy which included mo-
toric and sensory impairment, as well as partial trigeminal
and facial nerve paralysis, hearing impairment, headache
and dizziness. The most common symptom prior to radio-
therapy proved to be visual impairment, mostly double vi-
sion in 45 patients. Moreover, pre-existing double vision
and headache prior to radiotherapy showed the most
sizeable improvement, with symptom improvement or
stabilization in 34.5% (n = 38) for vision impairment and
41.8% (n = 46) for headaches. These improvements of pre-
therapeutic symptoms were achieved within a year after ir-
radiation. No more than 8.2% (n = 9) of all patients
reported a worsening of any given symptom. The most
common among worsening symptoms after RT were
headaches (8.2%, n = 9) and fatigue (7.3%, n = 8). An over-
view of predominant symptoms prior to particle therapy,
their grading according to CTCAE v4.0 and their relative
development during follow-up is presented in Table 4.
Discussion
The present manuscript evaluates the efficacy and tox-
icity profile of particle therapy for the treatment of 110
consecutive patients over a a period of 5 years, treated at
a single institution. Histology was predominantly benign
(WHO grade I) and mainly proton therapy was used, al-
though a combination of photon IMRT and a carbon ion
boost was used for a total of six patients with higher-
grade histology. None of the treated meningiomas had
Fig. 4 Overall survival calculated from primary diagnosis for patients
with skull base meningiomas treated with particle therapy,
regardless of histology
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previously been irradiated. Excellent overall local control
at the cost of very light toxicity was achieved with 100%
PFS after three and 96.6% PFS after 5 years and histology
appearing to significantly influence PFS.
The treatment of skull base meningiomas is a complex
clinical situation that requires careful interdisciplinary
evaluation. Due to the intricate anatomy of the skull base
and the distinct subset of symptoms and toxicities caused
by tumors there located, it has been discussed that skull
base meningiomas should be regarded as a separate entity
regarding outcome and treatment-associated toxicity [4].
Over the years, radiation therapy – and particularly
high-precision techniques such as FSRT or IMRT – has
evolved to become a central pillar in the multimodal
treatment of meningiomas. Several groups have shown
high efficacy with minimal toxicity [4, 6, 15]: One of the
largest collectives of skull base meningiomas treated
with photon IMRT or FSRT and with a median follow-
up of 107 months has been described at our institution,
showing a local control rate of 95% at 5 years and 88%
at 10 years [4]. Histology (WHO grade I vs. grades II
and III) proved to be an important prognostic factor, sig-
nificantly impacting PFS. These data have been con-
firmed by several similar studies performed at other
institutions: Kaul et al. have described PFS to be 93.8%
after 5 years for 318 patients with benign meningeomas
treated with FSRT [16]. In a separate series focusing ex-
clusively on skull base meningiomas PFS was similar for
low-risk histology and 41.8% after 5 years for high-risk
histologies [17]. Minniti et al. found a PFS rate of 96% at
Table 3 Acute and late treatment-related toxicity
Acute treatment-related toxicity Late treatment-related toxicity
Side effect low grade (CTCAE I-II) high grade (CTCAE III or higher) low grade (CTCAE I-II) high grade (CTCAE III or higher)
n= % n= % n= % n= %
focal alopecia 70 63.6% 0 0.0% 1 0.9% 0 0.0%
fatigue 52 47.3% 0 0.0% 10 9.1% 1 0.9%
skin irritation 44 40.0% 0 0.0% 0 0.0% 0 0.0%
headache 25 22.7% 0 0.0% 10 9.1% 0 0.0%
nausea 23 20.9% 1 0.9% 0 0.0% 0 0.0%
facial pain 12 10.9% 0 0.0% 2 1.8% 0 0.0%
dysgeusia 8 7.3% 0 0.0% 4 3.6% 0 0.0%
lymphedema 7 6.4% 0 0.0% 3 2.7% 0 0.0%
xerostomia 5 4.5% 0 0.0% 4 3.6% 0 0.0%
mucositis 1 0.9% 1 0.9% 1 0.9% 0 0.0%
radionecrosis 0 0.0% 0 0.0% 0 0.0% 3 2.7%
Table 4 Predominant symptoms prior to particle radiotherapy and their relative improvement development during follow-up










(CTCAE III or higher)
stable or improvement worsening
n= % n= % n= % n= % n= % n= %
visual impairment 35 31.8% 10 9.1% 28 25.5% 11 10.0% 38 34.5% 6 5.5%
headaches 35 31.8% 0 0.0% 27 24.5% 1 0.9% 46 41.8% 9 8.l2%
hearing impairment 25 22.7% 3 2.7% 25 22.7% 2 1.8% 33 30.0% 3 2.7%
motoric impairment 19 17.3% 1 0.9% 15 13.6% 2 1.8% 20 18.2% 1 0.9%
sensory impairment 14 12.7% 0 0.0% 12 10.9% 0 0.0% 16 14.5% 2 1.8%
dizziness 13 11.8% 0 0.0% 9 8.2% 0 0.0% 21 19.1% 2 1.8%
facial pain 13 11.8% 0 0.0% 9 8.2% 0 0.0% 21 19.1% 2 1.8%
cognitive impairment 11 10.0% 1 0.9% 14 12.7% 2 1.8% 16 14.5% 4 3.6%
seizures 9 8.2% 1 0.9% 2 1.8% 1 0.9% 9 8.2% 1 0.9%
fatigue 6 5.5% 0 0.0% 15 13.6% 1 0.9% 42 38.2% 8 7.3%
nausea 4 3.6% 0 0.0% 9 8,2% 0 0,0% 22 20.0% 0 0.0%
mucositis 0 0.0% 0 0.0% 1 0,9% 1 0,9% 2 1.8% 0 0.0%
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3 years and 93% at 5 years in a series of 52 patients with
large skull base meningiomas treated with FSRT [18].
Kessel et al. comprehensively reviewed recent literature
on the subject and published another large series of 260
patients treated with FSRT or IMRT and including 16%
high-risk histologies. They found a PFS rate after 5 years
of 87.1% and 54.9% for low-risk and high-risk histologies
respectively. Futhermore, patient-reported outcome showed
very mild toxicity with no more than 3.0% of patients ex-
periencing worsened or new symptoms ≥3 during RT and
the first 6 months thereafter [15].Our results have shown
that proton therapy can achieve similarly excellent local
control, though continuous long-term follow-up is war-
ranted. Reported data on toxicity and symptom response to
treatment is very similar to the results achieved in the
current analysis with only mild acute toxicity, the majority
of patients showing either stable or improved symptoms
during long-term follow-up.
One of the main rationales for the use of particle ther-
apy lies in its higher dose conformity, potentially allow-
ing for better OAR sparing and the reduction of side
effects [19–21]. The energy-deposition of accelerated
photons occurs continuously over a comparably wide
range of penetration depths through tissue [22]. The im-
proved dose distribution of particle therapy is achieved
by exploiting the physical characteristics of particle ir-
radiation where the maximum dose deposition occurs
within the sharply defined Bragg peak [9]. By varying the
particle energy, the position of the Bragg peak can be al-
tered. Particle therapy has been shown to be superior to
photon-based techiques in terms of sparing OAR and in
terms of target dose homogeneity/conformity with car-
bon ions showing slightly superior dose distributions
compared to protons [23, 24]. Arvold et al. observed a
significant dose reduction to neurocognitive, visual and
auditory organs achieved by proton irradiation as com-
pared to photon RT. Furthermore, they found protons to
reduce the risk of developing a radiologically-induced or
associated secondary malignancy by half [1]. Other publi-
cations showed a sizeable improvement of pre-exstisting
clinical symptoms in up to 47% of patients treated with
proton radiotherapy for meningiomas, to which our re-
sults compare favorably [10, 25]. We could observe a clear
tendency towards improvement that was most prominent
in patients suffering from visual impairment, mostly diplo-
pia. 34.5% of all patients showed stabilization or improve-
ment regarding eye-related symptoms and 41.8% regarding
headaches, corresponding to 77.8% of the patients reporting
pre-therapeutical eye-related symptoms and 94.3% of the
patients reporting headaches respectively.
In recent years the body of literature on treating men-
ingiomas with proton therapy has steadily grown and to
date there are several publications describing adequate-
sized collectives with a median follow-up of 32 to
84 months: Vlachogiannis et al. recently published a
retrospective analysis on 170 patients with grade I men-
ingiomas, 155 of which were located at the skull base,
who received hypofractionated proton therapy over a
period of 13 years. Median follow-up was 84 months
and authors reported PFS rates of 93% and 85% at five
and 10 years respectively. Main differences in compari-
son to the current work were the use of passive scatter-
ing and the hypofractionated dose regime of 3–8
fractions at 5 or 6 Gy(RBE) per fraction, translating
approximately to an EQD2 (equivalent dose in 2-Gy-
fractions) of 43 Gy.
Halasz et al. were the first to describe a radiosurgical
approach for proton therapy in meningiomas [10]. They
analysed a group of 50 patients treated with proton
stereotactic radiosurgery at a dose of 13 Gy prescribed
to the 90% isodose, achieving a three-year acturial tumor
control rate of 94% and toxicity rates similar to those de-
scribed above. The regarded collective included only
small tumor volumes and low-risk histologies. The data
suggest that a hypofractionated or even radiosurgical ap-
proach, as has been extensively evaluated for photon
therapy, might be a feasible and well-tolerated approach
for proton therapy as well and achieve satisfactory
results [26].
A recent retrospective study by Murray et al. described
the outcome of 96 meningioma patients treated with
pencil beam scanning proton therapy at Paul Scherrer
Institute in Switzerland over a 10 year period [27]. 63.5%
were low-risk and and 36.5% high risk meningiomas.
The authors reported an estimated 5-year local control
(5y-LC) rate of 95.7% for the low-risk group and 68% for
the high-risk group, showing consistency with the previ-
ously discussed literature and the results of our current
work. Five-year grade ≥ 3 toxicity-free survival was 89.1%.
The authors reported on identifying several prognostic
factors for local failure beside histology (p < 0,001), One
such factor was the timing of particle therapy (initial vs.
for recurrence or progressive disease) with patients treated
initially showing favorable outcome; furthermore tumors
of the skull base showed favorable outcome vs. non-skull
base (p = 0,14), as did female patients vs. males (p = 0,32).
However, none of those factors was tested in multivariate
analysis, thus their predictive value should be interpreted
with care.
DiBiase and colleagues revealed the size of the GTV to
be a significant prognostic factor, since in their described
collective of 162 patients treated with Gamma Knife SRS,
patients with smaller tumor volumes had longer survival
rates with a 5-year overall survival of 100% compared to
59.7% for larger lesions [28].
A small prospective randomized series by Sanford et
al. has tested the effect of dose escalation using a com-
bination of photon and proton therapy for the treatment
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of low-risk meningiomas with a median follow-up of
17,1 years [29]. While overall local control of 98% at
10 years and 90% at 15 years was excellent, no signifi-
cant benefit could be shown for the use of 63 Gy(RBE)
over 55,8 Gy(RBE). However, dose escalation might be
beneficial for the treatment of high-risk meningioma pa-
tients who show less favorable outcomes with established
dose regimens. 5y-LC rate for high-risk meningiomas was
75% in our analysis and though patient number was small,
results are comparable to figures reported in recent litera-
ture of 50–81% for IMRT or proton therapy, depending
on WHO grade [27, 30, 31].
Adeberg et al. could within the high-risk collective iden-
tify the WHO grade as prognostic factor for PFS with
higher grade yielding inferior PFS (p = 0,017) [30]. Not-
ably, the results of McDonald et al. support the rationale
of dose escalation for high-risk meningiomas, achieving
5y-LC rates of 87.5% for a radiation dose > 60 Gy(RBE)
compared to 50% for ≤60 Gy(RBE) of proton RT (p =
0,038) [31]. Regarding dose escalation in a highly radio-
sensitive region such as the skull-base, the use of heavier
ions such as carbon ions with their potentially superior
dose distribution and biological advantages attributed to
the increased relative biological effiectiveness (RBE) could
prove beneficial and may lead to higher local tumor con-
trol rates [9, 32]. In a small prospective phase I/II trial
conducted at our institution in 2010 on the administration
of a carbon ion boost after photon radiotherapy for 10 pa-
tients with high-risk meningiomas, we achieved promising
results with 5- and 7-year local control rates of 86% and
72% [33]. Median cumulative dose in this analysis was
68 Gy(RBE) and the series included two previously irradi-
ated tumors. Building upon those results, we have initiated
the MARCIE trial, a prospective phase II trial evaluating
PFS, OS and toxicity for the postoperative bimodal irradi-
ation of atypical meningiomas Simpson grade 4 or 5 [3].
The trial is currently recruiting and the dose regimen of
50 Gy photon RT combined with 6 × 3 Gy carbon ion
boost that we applied to the high-risk patients in this ana-
lysis is analogous to the concept employed in the MARCIE
trial. Though patient number was small for high-risk men-
ingiomas in our current analysis, results are in agreement
with previously published data for this dose regimen [33].
Certainly a potential benefit of particle therapy over
photon radiation techniques has to be verified clinically
and prospective trials are warranted. Several treatment
planning studies showed superiority for protons, particu-
larly for larger target volumes: For example, Phillips et al.
on reviewing different radiosurgical methods found that
particle RT results in supervior dose distributions than
photon-based linear accelarator (linac) methods for target
volumes > 25 ccm, though for smaller volumes results are
comparable while linac methods might offer higher flexi-
bility [34, 35]. Smith et al. supported these findings,
comparing linac-based photon RT to Gamma Knife SRS
and proton RT and calculating normal tissue complication
probability indices (NTCP) based on the dose conformity
of the resulting treatment plans and using a logistic model
based on the tolerance data by Rubin et al. and Emami et
al. [36]. While photon SRS techniques proved superior for
small spherical targets, protons had the lowest NTCP for
large (> 15 ccm) and peripheral target volumes (13,5 for
protons vs. 17,0–33,5 for linac) [37].
To date, our analysis represents the largest group of pa-
tients with skull base meningiomas treated with particle
therapy, including both protons and carbon ions, in a sin-
gle institution. Limitations of this analysis include the rela-
tively short follow-up period, its retrospective character
and the small number of both high-risk histologies and
patients treated with carbon ions, limiting the possibility
to perform meaningful subgroup analyses. The median
follow-up in this series at 46,8 months – though substan-
tial – is still relatively short when compared to other stud-
ies available, especially in the field of precision photon RT.
In the light of the benign nature of low-grade meningi-
omas and predicted long-term tumor-control and overall
survival continuous follow-up is warranted. Regarding the
different physical and biological characteristics of particle
therapy, potential long-term effects are of special interest.
Currently particle therapy patients at our institution are
included in a close-knit and rigorous follow-up regimen
and potential late side effects are documented in a pro-
spective database with dedicated institutional funding for
long-term evaluation [12].
To conclusively demonstrate the clinical benefits of
particle therapy there is currently a lack of a prospective
comparison to advanced photons. Prospective clinical
trials have since been initiated at several institutions to
further establish the role of particle therapy for the treat-
ment of certain subgroups of intracranial menigiomas.
Conclusion
In conclusion, particle therapy offers an excellent treat-
ment option for patients with meningiomas of the skull
base with long-term tumor control-rates and low tox-
icity. Compared to outcome reported on the treatment
of skull base meningiomas in the literature, the results
of our recent study compare favorably. Altough for this
entity with its favorable outcome still longer follow-up is
warranted, our results are in accordance with previous
series of skull base meningiomas treated with particle ther-
apy. Nonetheless, prospective studies with longer follow-up
will be necessary to further confirm the role of particle
radiotherapy in meningiomas of the skull base. Due to the
excellent results with advanced photons an improvement in
oncologic outcome by particle therapy in benign meningi-
omas will be difficult to demonstrate.
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